Hepatitis Monthly

Published by: Kowsar

Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?

Mohamad Amin Pourhoseingholi 1 , Sara Ashtari 1 and Seyed Moayed Alavian 2 , *
Authors Information
1 Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Middle East Liver Diseases Center (MELD), Tehran, IR Iran
Article information
  • Hepatitis Monthly: 14 (11); 25540
  • Published Online: November 22, 2014
  • Article Type: Editorial
  • Received: November 21, 2014
  • Accepted: November 22, 2014
  • DOI: 10.5812/hepatmon.25540

To Cite: Pourhoseingholi M A, Ashtari S, Alavian S M. Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?, Hepat Mon. Online ahead of Print ; 14(11):25540. doi: 10.5812/hepatmon.25540.

Abstract
© 2014, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Full Text
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments